Home›Research›Compare›Pramlintide vs Tirzepatide
Peptide ComparisonPramlintide vs Tirzepatide
Both are Metabolic peptides.
Pramlintide
Symlin
Half-life: ~48 minutes
No providers listed yet
Tirzepatide
Dual GLP-1
Half-life: ~5 days (once-weekly dosing)
577 providers listed
Tirzepatide carries stronger published evidence (RCT, 9 key studies) than Pramlintide (RCT, 3); both are research compounds.
Pramlintide
Half-life
~48 minutes
Tirzepatide
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Tirzepatide |
| Less frequent dosing (longer half-life) | Tirzepatide |
| More provider options (0 vs 577) | Tirzepatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Pramlintide
Tirzepatide
Pramlintide
Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and lept…
Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind,…
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive do…
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…
+5 more
About Pramlintide
Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Pramlintide
No established clinical contraindications
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Pramlintide
Not enough vendor pricing yet.
Tirzepatide
Where to source these peptides
Pramlintide
Browse directory →
Providers offeringTirzepatide
577 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated October 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Pramlintide vs Tirzepatide — Per-mg Price Comparison. Retrieved October 27, 2026, from https://peptidebase.io/peptides/compare/pramlintide/tirzepatide